Pacific Biosciences Of California (PACB) Cash from Operations Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 21.54% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 13.50% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 14.62% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 124.64% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -11.16% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 78.72% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -0.23% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -12.60% |
| 10 | Pacific Biosciences Of California | 381.79 Mn | 144.92 Mn | 12.64 Mn | -21.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.13% |
| Mar 31, 2026 | -1.44% |
| Dec 31, 2025 | 37.78% |
| Sep 30, 2025 | 58.85% |
| Jun 30, 2025 | 45.86% |
| Mar 31, 2025 | 41.79% |
| Dec 31, 2024 | 46.75% |
| Sep 30, 2024 | 30.25% |
| Jun 30, 2024 | -30.00% |
| Mar 31, 2024 | 20.07% |
| Dec 31, 2023 | 4.96% |
| Sep 30, 2023 | -3.37% |
| Jun 30, 2023 | 31.08% |
| Mar 31, 2023 | -19.82% |
| Dec 31, 2022 | -91.01% |
| Jun 30, 2022 | -285.46% |
| Mar 31, 2022 | -242.06% |
| Dec 31, 2021 | -122.31% |
| Jun 30, 2021 | 33.95% |
| Mar 31, 2021 | -130.66% |